its a shame. The drug is yet to complete its P2. Why is the streetdotcom headline calling it a blockbuster announcement soon ? Shameless of streetdotcom to publish this headline.
you said: "i don;t know how to invest so I want to blame"
So let me get this straight joe. do you invest in a company not listening to management's words ?
do you invest in companies where the management is WAY OFF (euphemism here) on their guidance ? Joe you are truly awesome.
My speculation is this guy is paid to defend the shady management that sold their stock to me at $12.5 by hyping under guise of forward looking statement.
Did mgmt really believe fusilev will grow from 2012 and did mgmt really believe in DEC 2012 that entry of generic leucovorin will not impact fusilev sales?
this guy seems to be paid to defend the management and hype the duds in the pipeline.
can anyone defend the record of this management ? virtually every forward looking statement made in 2012 is proven wrong by not a mile but 10k miles.....Fusilev, Folotyn, Zevalin
moreover we don't have access to 1000's of p2 ready or p2 completed assets of private biotech companies nor are many of these companies public.
If I was running taro, I would hire the very best biotech analysts and dedicate about 10 such analysts to scout for acquisitions.
the ONLY way to take it to the next level is getting a few specialty assets. You can't take this to the next level by just making more generics imho. By taking it to next level , i mean making this a multibagger from here...now taro sports a $7b market cap. I do think if Novexatin clinical results are successful , it can make this a mutlibagger from here. However, the company needs to have 5 novexatin-like assets (each addressing $5b market) even if they have diversify to other specialty areas like opthomology, etc. I cannot believe Gilead is $160b market cap and has made this achievement so fast .
esp after Feb 2013 the board n management have been working loyally for all shareholders. why invest in other managements?
Gilead paid $11b for pharmaasset primarily for solvadi (just started p3 trial then)....Now just that drug solvadi is clocking $12b in annual sales.
This is how right p2 or p3 specialty acquisition can add value to shareholders and take the company to the next level.
These are my forward looking statements under the SEC act of 1995 I will not revise these forward looking statements as things change. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those anticipated. Such statements are based on management's beliefs
Zevalin - can do $300m in a few years
Folotyn - we can double sales in a few years
Fusilev - we will grow
from todays SA article
"Yes, the price was steep but clearly the acquisition has been anything but a "drag on profits through 2014." Instead, Gilead executed flawlessly in rapidly bringing Sovaldi through Phase 3 studies to NDA approval in Dec 2013. In retrospect, the pricey acquisition of Pharmasset has turned out to be the most prescient deal in the pharma industry in recent memory, perhaps ever. Jeffries estimates total revenue of $200 billion to year 2030 - an average of $12.5B per year. The $11B price tag was an incredible bargain in retrospect. With the extraordinarily successful launch of Sovaldi, Gilead has become one of the most amazing stories in American industry. And the story is far from over."
the word "sustainable" needs to be defined. I have one definition. you have one. Mr Shanghvi likely has another.
as far as I am concerned, if it sustains for 2 years it is good...as then Taro with its newer pipeline will get other pricing opportunities that can more than mitigate the slack in its existing pricing opportunities when new competition enters in clobex, etc
I think taro should review this specialty opportunity
Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of back of the eye. Its principal product candidate, Fovista, is in Phase 3 clinical development for use in combination with anti-VEGF drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry and wet forms of AMD. The company was founded in 2007 and is based in New York, New York.
i am happy to be long term shareholder. when i entered this was one was special situation play.
Great low-risk diversified business, still undervalued and excellent track record(38% roi for 20 years in Sun) of the controlling shareholder. Also, most importantly the controlling shareholder seems to have accepted to work for ALL Shareholders(started after they canceled the "offer". this is becoming apparent since Aug 2013..they in-licensed novexatin)...so as of now I expect to hold this one to eternity. I expect Taro to makes some bold specialty acquisitions maybe in the opthamology or other specialty space.
Again, I am not RIA...do your own dd. And my decisions can change esp if I find a better investment (doubt it).
how long have you been in taro?
Way undervalued at $180.
Remember cs target of $150 was based of 50% price hike sustainability.
Also cs uses 9 times ebitda. Agila-mylan deal closed in DEC 2013 for 18.6 times ebitda
Also row potential is not fully tapped yet
As well novexatin ..it will be in $6b market
Hoping they will use 700m cash to make acquisitions soon
Hoping minority nominee also enters board at some point
Valery - wait 2 more days friend. There is gotta be more 13f considering spike in volume.
There are only 2 printing presses:one is bernake and the other is taro!
In a report published Friday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $15.00 price target on Spectrum Pharmaceuticals (NASDAQ: SPPI).